Source: Murphy/CDC via Getty Images

Merck to Submit Ebola Vaccine for Approval by End of 2017

  • Merck to provide 300,000 doses of vaccine starting in May
  • Vaccine to be made available for more trials, emergency use

Merck & Co. has signed an agreement with Gavi, the world’s biggest funder of vaccines for developing countries, to submit its experimental Ebola vaccine for regulatory approval by the end of 2017.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.